Background & aim: As on date, no specific treatment is available for devastating COVID-19 (SARS-CoV-2) infection. This pandemic viral infection has affected over 200 countries within a very short time and created a calamitous situation across the globe. As per WHO guidelines, the treatment is mainly symptomatic and supportive. This clinical protocol has not proven sufficient to save the lives of COVID-19 patients suffering from diabetes or having underlying liver diseases; hence there is utmost need to tackle this situation by other means such as Convalescent Plasma (CP) therapy.
Methods: A comprehensive literature survey was carriedout using Elsevier, PubMed, Taylor & Francis, Springer, Nature and Google search engines.
Results: The patients suffering from diabetes or liver dysfunction or any other underlying diseases are at greatest risk of SARS-CoV-2 infection. From the study, it is proved that plasma collected from the recovered patients of viral infection has considerable potential to treat the viral disease without the occurrence of adverse effects.
Conclusion: The CP therapy can be a possible life saving alternative to treat critical COVID-19 patients having diabetes or underlying liver dysfunction. Hence, randomised clinical trials are recommended at the earliest to save the lives of infected individuals of COVID-19.
Keywords: ACE2; COVID-19; Convalescent plasma; Diabetes; Liver diseases; Neutralizing Antibodies; SARS-CoV-2.
Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no competing interests.
Focus on Receptors for Coronaviruses with Special Reference to Angiotensin-converting Enzyme 2 as a Potential Drug Target - A Perspective.Endocr Metab Immune Disord Drug Targets. 2020 Apr 27. doi: 10.2174/1871530320666200427112902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2020. PMID: 32338224
Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.Aging (Albany NY). 2020 Apr 22;12(8):6536-6542. doi: 10.18632/aging.103102. Epub 2020 Apr 22. Aging (Albany NY). 2020. PMID: 32320384 Free PMC article.
Counter-regulatory 'Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected patients.Infect Disord Drug Targets. 2020 May 17. doi: 10.2174/1871526520666200518073329. Online ahead of print. Infect Disord Drug Targets. 2020. PMID: 32418532
Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.J Med Virol. 2020 May 1. doi: 10.1002/jmv.25961. Online ahead of print. J Med Virol. 2020. PMID: 32356910 Review.
Features, Evaluation and Treatment Coronavirus (COVID-19).2020 Apr 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan–. StatPearls. 2020 Jan–. PMID: 32150360 Free Books & Documents. Review.
- Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Feb 3 doi: 10.1038/s41586-020-2012-7. [Epub ahead of print] - DOI
- International Diabetes Federation IDF diabetes atlas. 2019. https://www.diabetesatlas.org/en/ 9th edn. Brussels, Belgium.
- Ruan Q., Yang K., Wang W., Jiang L., Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020 Mar 3 doi: 10.1007/s00134-020-05991-x. - DOI
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020 Feb 24 doi: 10.1001/jama.2020.2648. - DOI